Table 2.
Differences between PTLD cases and age-, sex-, race- and transplanted organ-matched controls in a single-center cohort of renal transplant recipients, 2010–2019.
| Variable | Cases n = 17 (%) | Controls n = 34 (%) | Total n = 51 (%) | p-value |
|---|---|---|---|---|
| Median follow-up time from transplant, months | 103.7 | 49.8 | 57.1 | N/A |
| Median age at transplant, years | 48.23 | 47.73 | 47.8 | 0.392 |
| Interquartile range | 31.8–57.1 | 32.2–57.9 | 31.8–57.9 | |
| Sex | N/A | |||
| Male | 10 (58.8) | 20 (58.8) | 21 (41.2) | |
| Female | 7 (41.2) | 14 (41.2) | 30 (58.8) | |
| Race | N/A | |||
| African American | 5 (29.4) | 10 (29.4) | 15 (29.4) | |
| Non-African American | 12 (70.6) | 24 (70.6) | 36 (70.6) | |
| Ethnicity | 0.624 | |||
| Hispanic | 1 (6.3) | 1 (3.2) | 2 (4.3) | |
| Non-Hispanic | 15 (93.8) | 30 (96.8) | 45 (95.7) | |
| Unknown | 1 | 3 | 4 | |
| Donor type | 0.739 | |||
| Deceased | 10 (58.8) | 20 (58.8) | 30 (61.2) | |
| Living | 6 (35.3) | 13 (38.2) | 19 (38.8) | |
| Unknown | 1 | 1 | 2 | |
| Re-transplant | 0.773 | |||
| Yes | 2 (11.8) | 5 (14.7) | 7 (13.7) | |
| No | 15 (88.2) | 29 (85.3) | 44 (86.3) | |
| EBV serostatus | 0.063 | |||
| Donor−/recipient − | 1 (7.1) | 0 | 1 (2.6) | |
| Donor+/recipient − | 6 (42.9) | 2 (8.3) | 8 (21.1) | |
| Donor−/recipient + | 0 | 1 (4.2) | 1 (2.6) | |
| Donor−/recipient + | 7 (50.0) | 21 (87.5) | 28 (73.7) | |
| Unknown | 3 | 10 | 13 | |
| Immunosuppression | 0.438 | |||
| Belatacept | 3 (27.3) | 9 (47.4) | 12 (40) | |
| Tacrolimus/other | 8 (72.7) | 10 (52.6) | 18 (60) | |
| Unknown | 6 | 15 | 21 | |
| Graft rejection of any gradea | 0.512 | |||
| Yes | 12 (54.6) | 5 (41.7) | 17 (50) | |
| No | 10 (45.4) | 7 (58.3) | 17 (50) | |
| Unknown | 5 | 12 | 17 | |
| Graft loss | 0.0957 | |||
| Yes | 4 (23.5) | 2 (5.9) | 6 (11.8) | |
| No | 13 (76.5) | 32 (94.1) | 45 (88.2) |
p-values calculated using exact conditional logistic regression.
a
Rejection grades included grades 1, 2, 3, and borderline.